[Changes of serum epithelial neutrophil-activating peptide-78 in patients with endometriosis].
OBJECTIVE
To investigate the role of serum epithelial neutrophil-activating peptide-78 (ENA-78) in the pathogenesis of endometriosis.


METHODS
Serum concentrations of ENA-78 were measured by means of enzyme-linked immunosorbent assay (ELISA) in 42 patients with endometriosis (20 in stages I and II and 22 in stages III and IV) in comparison with 25 women without endometriosis (control group).


RESULTS
Serum concentrations of ENA-78 were significantly higher in endometriosis group than in the control group (2.97+/-1.91 ng/ml vs 0.72+/-0.24 ng/ml, P>0.001), and ENA-78 levels in stages III and IV were significantly higher than those in stages I and II (4.48+/-1.25 ng/ml vs 1.30+/-0.74 ng/ml, P>0.001). Significant difference in ENA-78 levels between follicular phase and luteal phase was found in neither of the groups.


CONCLUSIONS
Patients with endometriosis have elevated serum ENA-78 levels, which might be a pathogenic factor of endometriosis.
Cai
Zhu-Hua
ZH
Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. caizhua12@hotmail.com
He
Yuan-Li
YL
Peng
Dong-Xian
DX
D000328:Adult; D054365:Chemokine CXCL5; D019743:Chemokines, CXC / Q000097:blood*; D004715:Endometriosis / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged
C486263:CXCL5 protein, human; D054365:Chemokine CXCL5; D019743:Chemokines, CXC